Skip to Content

Tresiba Approval History

Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients one year of age and older with diabetes mellitus.

Development History and FDA Approval Process for Tresiba

Dec 19, 2016Approval Novo Nordisk Receives FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents With Diabetes
Sep 25, 2015Approval FDA Approves Tresiba (insulin degludec) for Diabetes Mellitus
Jun 11, 2012Investigational Ultra Long-Acting Insulin Degludec Reduced Rates of Nocturnal Hypoglycemia in Type 2 Diabetes Patients Versus Insulin Glargine

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.